ADC Therapeutics SA has announced the discontinuation of the Phase 2 LOTIS-9 trial evaluating Zynlonta and rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma (DLBCL). The decision follows a voluntary pause in enrollment due to potentially excessive respiratory-related events, including seven fatal events. The FDA has placed a partial clinical hold on the trial for new patient enrollment. ADC Therapeutics' shares are down 6.00%.